SynthesisFrontiers in immunology2025

Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma.

Jaffer A Ajani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.